Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction
NCT ID: NCT04421274
Last Updated: 2020-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
43 participants
INTERVENTIONAL
2008-05-01
2011-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases
NCT01234181
Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients
NCT03047772
Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)
NCT01307371
Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease
NCT02504437
Safety and Efficacy of Bone Marrow Cell Transplantation in Humans Myocardial Infarction
NCT00437710
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BM-MSCs group
Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )
Bone marrow mesenchymal stem cells transfer
Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times
Best medical treatment
Refer to the latest medication guidelines and give the best medication to the patients
Percutaneous coronary intervention
Percutaneous coronary intervention
Control group
Receive the best medication, percutaneous coronary intervention
Best medical treatment
Refer to the latest medication guidelines and give the best medication to the patients
Percutaneous coronary intervention
Percutaneous coronary intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bone marrow mesenchymal stem cells transfer
Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times
Best medical treatment
Refer to the latest medication guidelines and give the best medication to the patients
Percutaneous coronary intervention
Percutaneous coronary intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed acute ST-elevation myocardial infarction (STEMI)
* STEMI onset \<1 month
* Successful vascular remodeling, blood flow of infarct-related blood vessels recovered to TIMI level 3
* All patients included in the study signed an informed consent form and promised to complete all follow-up plans
Exclusion Criteria
* High cardiac block and no pacemaker control
* Liver or renal dysfunction (ALT\>80U/ L, Cr\> 440mmol / L)
* Bleeding disorders, malignant tumors
* Autoimmune disease or any serious fatal disease
* Contraindications for coronary intervention
* Combined with other heart disease: congenital heart Disease (ventricular deficiency, atrial deficient, patent ductus arteriosus and other congenital alformations),primary valvular disease, active myocarditis, pulmonary heart disease,hyperthyroidism, mucous edema heart disease and so on
* Mental illness, no self-awareness, and no precise expression and cooperation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Peking Union Medical College Hospital
OTHER
Beijing Tongren Hospital
OTHER
Affiliated Hospital of North Sichuan Medical College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Third Hospital of Mianyang
Mianyang, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang R, Yu J, Zhang N, Li W, Wang J, Cai G, Chen Y, Yang Y, Liu Z. Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction: single-blind, multicenter, randomized controlled trial. Stem Cell Res Ther. 2021 Jan 7;12(1):33. doi: 10.1186/s13287-020-02096-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ScPHFPC-100306
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.